Optovue, Inc.
RTVue XR is being premiered at the Annual Meeting of the American Society of Cataract and Refractive Surgeons
FREMONT, CA, April 23, 2012 – Optovue, a pioneer in spectral-domain optical coherence tomography (SD-OCT), announces that it has received FDA 510(k) clearance of the XR version of their flagship RTVue® FD-OCT system. Bringing 70,000 A-scans-per-second to spectral-domain OCT, the updated XR version offers clinicians speed that no currently cleared SD-OCT system can match. Together with real-time tracking and the updated SharpVue™ feature, the speed of the RTVue XR can reduce the incidence of motion artifacts while allowing for greater scan averaging output. This results in excellent tissue detail of the retina and choroid layers of the eye. Premiering at the ASCRS in Chicago, RTVue XR is scheduled to be available in the third quarter of 2012.
"This FDA clearance affirms RTVue's position as the market leader, now with the fastest scan speed of any FDA cleared device available," states Jay Wei, CEO of Optovue. "We continue to leverage our experience in OCT product development and Fourier-domain technology to serve the needs of physicians and patients."
RTVue was the first FDA cleared Spectral-Domain OCT launched in the United States, and also the first OCT cleared by the U.S. Food and Drug Administration for both corneal and retinal imaging. The RTVue provides an all-in-one solution for posterior and anterior high-speed, high-resolution OCT imaging, offering five-micron resolution, high-magnification imaging of the cornea, angle and anterior crystalline lens, pachymetry mapping, keratoconus analysis, as well as retina and glaucoma scanning and analysis functions.
The RTVue can be used to calculate the total power of the cornea in eyes that have undergone corneal refractive surgery, with Optovue’s proprietary corneal segmentation algorithm. Furthermore, the RTVue directly measures posterior corneal power and does not rely on good preoperative vision or a complete clinical record.
About Optovue® (www.optovue.com)
Optovue, Inc. is a privately-held ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular disease. Optovue has achieved widespread market success through a combination of unique data analysis design, a reputation for excellent customer service, and rapid innovation of its technology in response to physician feedback. The company is headquartered in Fremont, CA, with operations in Encinitas, CA and European operations in Germany.
Contact:
Paul Kealey
Sr. Vice President Marketing
[email protected]
John Talarico
Vice President Regulatory
[email protected]